Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 10 September 2021, including: US industry warns over pricing; a setback for another gene therapy; a Phase II blow for Novartis’s transplant drug; Actemra shortages cause CAR-T challenges; and Sweden’s Sobi set to go private.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pharma On Its Back Foot As US Drug Price Reform Advances" - Scrip, 8 Sep, 2021.)
(Also see "Novartis's Big Hopes For Transplant Drug Blown Apart" - Scrip, 3 Sep, 2021.)
(Also see "COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers" - Scrip, 6 Sep, 2021.)
(Also see "Sobi To Go Private In $8.1bn Buyout That Appreciates Growth Strategy" - Scrip, 2 Sep, 2021.)